{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:17:33Z","timestamp":1792282653603,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["638035"],"award-info":[{"award-number":["638035"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["111267"],"award-info":[{"award-number":["111267"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","award":["5240\/5-2"],"award-info":[{"award-number":["5240\/5-2"]}],"id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","award":["HE 5240\/6-2"],"award-info":[{"award-number":["HE 5240\/6-2"]}],"id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00277-019-03713-y","type":"journal-article","created":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T11:16:16Z","timestamp":1558178176000},"page":"1905-1918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo"],"prefix":"10.1007","volume":"98","author":[{"given":"Nidhi","family":"Jyotsana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuhar","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramachandramouli","family":"Budida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Scherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kuchenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Noyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Grote-Koska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbinian","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Vornlocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Keith","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euan","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Cullis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,18]]},"reference":[{"issue":"7","key":"3713_CR1","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6(7):e441","journal-title":"Blood Cancer J"},{"issue":"9","key":"3713_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369(9):819\u2013829","journal-title":"N Engl J Med"},{"issue":"1","key":"3713_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376(1):41\u201351","journal-title":"N Engl J Med"},{"issue":"4","key":"3713_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH III, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O (2019) Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139(4):431\u2013443","journal-title":"Circulation"},{"key":"3713_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","volume":"203","author":"C Lorenzer","year":"2015","unstructured":"Lorenzer C, Dirin M, Winkler AM, Baumann V, Winkler J (2015) Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 203:1\u201315","journal-title":"J Control Release"},{"key":"3713_CR6","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1038\/mtna.2013.65","volume":"2","author":"RL Rungta","year":"2013","unstructured":"Rungta RL, Choi HB, Lin PJC, Ko RWY, Ashby D, Nair J, Manoharan M, Cullis PR, MacVicar BA (2013) Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol Ther Nucleic Acids 2:e136","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"3713_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/leu.2017.269","volume":"32","author":"N Jyotsana","year":"2018","unstructured":"Jyotsana N, Sharma A, Chaturvedi A, Scherr M, Kuchenbauer F, Sajti L, Barchanski A, Lindner R, Noyan F, S\u00fchs KW, Grote-Koska D, Brand K, Vornlocher HP, Stanulla M, Bornhauser B, Bourquin JP, Eder M, Thol F, Ganser A, Humphries RK, Ramsay E, Cullis P, Heuser M (2018) RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo. Leukemia 32(1):224\u2013226","journal-title":"Leukemia"},{"key":"3713_CR8","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1038\/mtna.2012.28","volume":"1","author":"NM Belliveau","year":"2012","unstructured":"Belliveau NM et al (2012) Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids 1:e37","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1\u20132","key":"3713_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","volume":"1510","author":"SC Semple","year":"2001","unstructured":"Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, Maurer N, Stark H, Cullis PR, Hope MJ, Scherrer P (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510(1\u20132):152\u2013166","journal-title":"Biochim Biophys Acta"},{"issue":"2\u20133","key":"3713_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0169-409X(01)00103-X","volume":"47","author":"IM Hafez","year":"2001","unstructured":"Hafez IM, Cullis PR (2001) Roles of lipid polymorphism in intracellular delivery. Adv Drug Deliv Rev 47(2\u20133):139\u2013148","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"3713_CR11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/pharmaceutics5030498","volume":"5","author":"YY Tam","year":"2013","unstructured":"Tam YY, Chen S, Cullis PR (2013) Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics 5(3):498\u2013507","journal-title":"Pharmaceutics"},{"issue":"1","key":"3713_CR12","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.1073\/pnas.1519273113","volume":"113","author":"S Weinstein","year":"2016","unstructured":"Weinstein S, Toker IA, Emmanuel R, Ramishetti S, Hazan-Halevy I, Rosenblum D, Goldsmith M, Abraham A, Benjamini O, Bairey O, Raanani P, Nagler A, Lieberman J, Peer D (2016) Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A 113(1):E16\u2013E22","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5405","key":"3713_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405):290\u2013293","journal-title":"Nature"},{"issue":"1","key":"3713_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1535-6108(02)00025-9","volume":"1","author":"BJ Druker","year":"2002","unstructured":"Druker BJ (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1(1):31\u201336","journal-title":"Cancer Cell"},{"issue":"24","key":"3713_CR15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O\u2019Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531\u20132541","journal-title":"N Engl J Med"},{"issue":"10","key":"3713_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","volume":"138","author":"R Kurzrock","year":"2003","unstructured":"Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M (2003) Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 138(10):819\u2013830","journal-title":"Ann Intern Med"},{"issue":"6","key":"3713_CR17","first-page":"2343","volume":"61","author":"E Laurent","year":"2001","unstructured":"Laurent E et al (2001) The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 61(6):2343\u20132355","journal-title":"Cancer Res"},{"issue":"5531","key":"3713_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876\u2013880","journal-title":"Science"},{"issue":"4","key":"3713_CR19","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bbrc.2004.05.113","volume":"319","author":"M Yamamoto","year":"2004","unstructured":"Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O (2004) The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR\/ABL fusion kinase. Biochem Biophys Res Commun 319(4):1272\u20131275","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"3713_CR20","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg E, Griffin JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines. Blood 95(11):3498\u20133505","journal-title":"Blood"},{"issue":"9","key":"3713_CR21","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S et al (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9):3472\u20133475","journal-title":"Blood"},{"issue":"4","key":"3713_CR22","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","volume":"101","author":"M Scherr","year":"2003","unstructured":"Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M (2003) Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101(4):1566\u20131569","journal-title":"Blood"},{"issue":"10","key":"3713_CR23","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood-2005-03-1283","volume":"106","author":"M Thomas","year":"2005","unstructured":"Thomas M, Gessner A, Vornlocher HP, Hadwiger P, Greil J, Heidenreich O (2005) Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 106(10):3559\u20133566","journal-title":"Blood"},{"issue":"2","key":"3713_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10238-007-0125-z","volume":"7","author":"M Koldehoff","year":"2007","unstructured":"Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH (2007) Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 7(2):47\u201355","journal-title":"Clin Exp Med"},{"key":"3713_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-4939-1538-5_17","volume":"1218","author":"M Koldehoff","year":"2015","unstructured":"Koldehoff M (2015) Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions. Methods Mol Biol 1218:277\u2013292","journal-title":"Methods Mol Biol"},{"key":"3713_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejpb.2018.06.018","volume":"130","author":"J Valencia-Serna","year":"2018","unstructured":"Valencia-Serna J, Aliabadi HM, Manfrin A, Mohseni M, Jiang X, Uludag H (2018) siRNA\/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo. Eur J Pharm Biopharm 130:66\u201370","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"3713_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125277","volume":"10","author":"G Urbinati","year":"2015","unstructured":"Urbinati G, Ali HM, Rousseau Q, Chapuis H, Desma\u00eble D, Couvreur P, Massaad-Massade L (2015) Antineoplastic effects of siRNA against TMPRSS2-ERG junction oncogene in prostate cancer. PLoS One 10(5):e0125277","journal-title":"PLoS One"},{"issue":"4","key":"3713_CR28","first-page":"823","volume":"36","author":"S Takenaka","year":"2010","unstructured":"Takenaka S, Naka N, Araki N, Hashimoto N, Ueda T, Yoshioka K, Yoshikawa H, Itoh K (2010) Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Int J Oncol 36(4):823\u2013831","journal-title":"Int J Oncol"},{"issue":"8","key":"3713_CR29","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1182\/blood-2005-08-3087","volume":"107","author":"M Scherr","year":"2006","unstructured":"Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A, Eder M (2006) Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107(8):3279\u20133287","journal-title":"Blood"},{"issue":"12","key":"3713_CR30","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2006-04-014845","volume":"108","author":"M Heuser","year":"2006","unstructured":"Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B, Ganser A (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108(12):3898\u20133905","journal-title":"Blood"},{"key":"3713_CR31","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.2147\/IJN.S34301","volume":"7","author":"YP Fang","year":"2012","unstructured":"Fang YP, Wu PC, Huang YB, Tzeng CC, Chen YL, Hung YH, Tsai MJ, Tsai YH (2012) Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. Int J Nanomedicine 7:4995\u20135005","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"3713_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrd2310","volume":"6","author":"A de Fougerolles","year":"2007","unstructured":"de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6(6):443\u2013453","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3713_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2050-7771-2-4","volume":"2","author":"U Testa","year":"2014","unstructured":"Testa U, Pelosi E, Frankel A (2014) CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res 2(1):4","journal-title":"Biomark Res"},{"issue":"2","key":"3713_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/leu.2015.252","volume":"30","author":"W Zeijlemaker","year":"2016","unstructured":"Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, Cloos J, Ossenkoppele GJ, Schuurhuis GJ (2016) A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia 30(2):439\u2013446","journal-title":"Leukemia"},{"issue":"2","key":"3713_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12288-013-0317-5","volume":"30","author":"S Dutta","year":"2014","unstructured":"Dutta S, Saxena R (2014) The expression pattern of CD33 antigen can differentiate leukemic from Normal progenitor cells in acute myeloid leukemia. Indian J Hematol Blood Transfus 30(2):130\u2013134","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"3713_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.canlet.2012.08.024","volume":"334","author":"D Landesman-Milo","year":"2013","unstructured":"Landesman-Milo D, Goldsmith M, Leviatan Ben-Arye S, Witenberg B, Brown E, Leibovitch S, Azriel S, Tabak S, Morad V, Peer D (2013) Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett 334(2):221\u2013227","journal-title":"Cancer Lett"},{"issue":"1","key":"3713_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bbrc.2004.12.137","volume":"328","author":"XD Yan","year":"2005","unstructured":"Yan XD et al (2005) The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun 328(1):57\u201362","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"3713_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A et al (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18(7):1357\u20131364","journal-title":"Mol Ther"},{"issue":"3","key":"3713_CR39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jconrel.2010.09.016","volume":"148","author":"PX Zhou","year":"2010","unstructured":"Zhou PX et al (2010) Uptake of synthetic low density lipoprotein by leukemic stem cells - a potential stem cell targeted drug delivery strategy. J Control Release 148(3):380\u2013387","journal-title":"J Control Release"},{"issue":"9189","key":"3713_CR40","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(99)09403-9","volume":"354","author":"JL Wiemels","year":"1999","unstructured":"Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G, Saha V, Biondi A, Greaves MF (1999) Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354(9189):1499\u20131503","journal-title":"Lancet"},{"key":"3713_CR41","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.1038\/ncomms7604","volume":"6","author":"X Ma","year":"2015","unstructured":"Ma X et al (2015) Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun 6:6604","journal-title":"Nat Commun"},{"issue":"5906","key":"3713_CR42","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"322","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, Downing JR (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322(5906):1377\u20131380","journal-title":"Science"},{"issue":"16","key":"3713_CR43","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373(16):1541\u20131552","journal-title":"N Engl J Med"},{"key":"3713_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fonc.2014.00054","volume":"4","author":"KM Bernt","year":"2014","unstructured":"Bernt KM, Hunger SP (2014) Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol 4:54","journal-title":"Front Oncol"},{"issue":"22","key":"3713_CR45","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059\u20132074","journal-title":"N Engl J Med"},{"issue":"1","key":"3713_CR46","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","volume":"16","author":"T O\u2019Hare","year":"2006","unstructured":"O\u2019Hare T, Corbin AS, Druker BJ (2006) Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 16(1):92\u201399","journal-title":"Curr Opin Genet Dev"},{"issue":"9","key":"3713_CR47","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","volume":"25","author":"JR Wright","year":"2007","unstructured":"Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25(9):1027\u20131032","journal-title":"J Clin Oncol"},{"issue":"20","key":"3713_CR48","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-11-0430","volume":"17","author":"DS Hong","year":"2011","unstructured":"Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, Andre V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G (2011) A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 17(20):6582\u20136591","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3713_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14728222.2018.1417390","volume":"22","author":"N Jyotsana","year":"2018","unstructured":"Jyotsana N, Heuser M (2018) Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer. Expert Opin Ther Targets 22(2):107\u2013121","journal-title":"Expert Opin Ther Targets"},{"issue":"10","key":"3713_CR50","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa1310523","volume":"373","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, Laborde RR, Wassie E, Schimek L, Hanson CA, Gangat N, Wang X, Pardanani A (2015) A pilot study of the telomerase inhibitor Imetelstat for myelofibrosis. N Engl J Med 373(10):908\u2013919","journal-title":"N Engl J Med"},{"issue":"9729","key":"3713_CR51","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","volume":"375","author":"TW Geisbert","year":"2010","unstructured":"Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, MacLachlan I (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375(9729):1896\u20131905","journal-title":"Lancet"},{"key":"3713_CR52","doi-asserted-by":"publisher","unstructured":"Huang X, Schwind S, Santhanam R, Eisfeld AK, Chiang CL, Lankenau M, et al (2016) Targeting the RAS\/MAPK pathway with miR-181a in acute myeloid leukemia. Oncotarget 7(37):59273-86. https:\/\/doi.org\/10.18632\/oncotarget.11150","DOI":"10.18632\/oncotarget.11150"},{"issue":"11","key":"3713_CR53","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1038\/leu.2015.139","volume":"29","author":"AM Dorrance","year":"2015","unstructured":"Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, Garzon R, Caligiuri MA, Bloomfield CD, Marcucci G (2015) Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia 29(11):2143\u20132153","journal-title":"Leukemia"},{"issue":"9","key":"3713_CR54","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1158\/1078-0432.CCR-12-3191","volume":"19","author":"X Huang","year":"2013","unstructured":"Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G (2013) Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res 19(9):2355\u20132367","journal-title":"Clin Cancer Res"},{"key":"3713_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11452","volume":"7","author":"X Jiang","year":"2016","unstructured":"Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, le Beau MM, Herold T, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, Chen J (2016) miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun 7:11452","journal-title":"Nat Commun"},{"issue":"15","key":"3713_CR56","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1158\/0008-5472.CAN-15-2949","volume":"76","author":"X Jiang","year":"2016","unstructured":"Jiang X, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen J (2016) Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res 76(15):4470\u20134480","journal-title":"Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03713-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T07:19:32Z","timestamp":1663485572000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03713-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,18]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["3713"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03713-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,18]]},"assertion":[{"value":"28 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Euan Ramsay is an employee of Precision Nanosystems. Pieter Cullis is founder of Precision Nanosystems. The other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}